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S37. CROSS-CULTURAL DIFFERENCES IN PANSS 
ITEM RATINGS: COMPARISONS OF SIX  
GEO-CULTURAL REGIONS
Kia Crittenden*1, Sayaka Machizawa1, H. Todd Feaster1, 
Jordan M. Barbone1, Bomi Hong1, Prateek Verma1, Wei Zhou1
1Signant Health
Background: While schizophrenia is observed in different parts of the world 
across countries, ethnicities, and races, research indicates cultural factors play 
significant roles in the phenomenology of this illness. Cultural norms and 
values affect manifestations of this pathology; more specifically, they affect how 
symptoms are expressed, experienced, and interpreted. Given that culture affects 
manifestations of schizophrenia, cultural factors should be considered in the as-
sessment of its symptoms in clinical trials. This study explores the differences 
and patterns in the Positive and Negative Syndrome Scale (PANSS) item ratings 
across different geocultural regions. Identifying such patterns can give insights 
into culturally sensitive assessment practices and aid in developing more effec-
tive rater training and data surveillance that consider unique cultural factors.
Methods: Data were obtained from an international group of raters from 
37 different countries, representing 6 geocultural regions across 13 different 
studies. As part of the rater training and qualification process for each 
of these studies, raters viewed and scored the 30-item PANSS based on a 
video-recorded PANSS interview that was administered using the Structured 
Clinical Interview-Positive and Negative Syndrome Scale (SCI-PANSS). 
Raters were deemed qualified if their scores fell within the defined acceptable 
item score ranges. Given the cultural diversity of the raters, the acceptable 
passing score ranges for each country were determined by a combination of 
expert opinion scores, group modal scores, and clinical analyses. Only the 
scores from raters who achieved qualification on their first scoring attempt 
were analyzed. The number of raters per geocultural regions included: Asia 
Pacific, n = 397; Eastern Europe, n = 412; Latin America, n = 88; Middle 
East/Africa, n = 29; North America, n = 339; and Western Europe, n = 129.
Results: A Shapiro-Wilk test for normality was conducted on the scores for 
each PANSS item and found all significantly different from a normal distri-
bution (all ps < .0001). A Kruskal-Wallis test for rank-ordered differences 
was conducted for each item for the influence of region on item score. Most 
items showed a significant influence of region on score after a Bonferroni 
correction was applied; most ps < .0001 with the following exceptions: N1, p 
< .001; G15, p < .05; P2, P7, N6, N7, G1, G6, G10, G12, and G13 were not 
significant. The most significant cross-regional differences were found with 
P1, P3 and P6, and these items were analyzed further with a post hoc Dunn 
test to understand cross-regional patterns. On P1, Asia Pacific and Eastern 
Europe were significantly lower than Latin America, North America, and 
Western Europe (all ps < .0008) but not Mideast/Africa. On P3, Western 
Europe were significantly lower than all other regions (all ps < .0005); Asia 
Pacific were significantly lower than Eastern Europe, North America, and 
Western Europe (all ps < .006). On P6, Asia Pacific and Eastern Europe 
were significantly lower than all other regions (all ps < .03).
Discussion: The present study suggests that ratings of schizophrenia 
symptoms are influenced by cultural factors. Cultural beliefs and behaviors 
seem to influence interpretations of schizophrenia pathology. Given that 
the PANSS is not standardized for cross-cultural contexts, it is important 
to consider cultural factors when using this scale in clinical studies. In ad-
dition, when developing rater training and data surveillance programs, ad-
justment of acceptable item score ranges for key PANSS items highlighted 
above for different geocultural region is recommended. Future studies 
should explore country-level patterning of ratings of the PANSS.
S38. EXPERT RATERS RELIABLY ASSESS 
PSYCHOMOTOR SLOWING IN PSYCHOSIS, BUT 
SELF-REPORT DOES NOT
Niluja Nadesalingam*1, Danai Alexaki1, Stephanie Lefebvre1, 
Florian Wüthrich1, Sebastian Walther1
1Translational Research Center, University Hospital of Psychiatry 
and Psychotherapy, University of Bern, Switzerland
Background: Motor abnormalities frequently occur in schizophrenia along 
with hallucinations, delusions, and negative symptoms. Psychomotor 
slowing (PS) is one of these motor abnormalities and is characterized 
by reduced levels of spontaneous gross motor activity as measured by 
actigraphy, slowed gait and slowing in fine motor tasks. Several reports 
indicated that 30–50% of schizophrenia patients are suffering from PS. 
Moreover, PS is associated with multiple disadvantages such as sedentary 
behavior, cardiometabolic risks and predicts poor treatment outcome and 
long-term cognition deficits. Therefore, there is a need to accurately and 
reliably evaluate PS in clinical settings.
In the current study, we anaylized how the gold-standard actigraphy 
corresponds to either self-report or expert ratings.
Methods: In the present study, we evaluated the motor behavior of 23 
patients suffering from schizophrenia spectrum disorders and 17 healthy 
controls using 3 distinct methods. (i) An observer rating scale: The 
Salpêtrière Retardation Rating Scale (SRRS), which is a 15 Items-scale 
ranging from 0 to 60 points measuring PS. A higher score indicates severe 
impairment. (ii) A  self-report Questionnaire: the International Physical 
Activity Questionnaire (IPAQ), in which the participant report their phys-
ical activity. It is a 7 Items-scale, which estimates the weekly metabolic 
commitment to walk and to perform physical activities of moderate and 
vigorous intensities. The higher the score, the more active was the person 
during the last week. (iii) the gold-standard actigraphy, which measures the 
gross motor activity of the participants for 24h by wearing an actiwatch on 
the non-dominant arm. It integrates all movements of a subject whithin 24 
hours into one parameter.
Results: Both the physical activity measured with wrist activity (t(35) = 3.901, 
p < .005; controls: m  =  349099, sd  =  112853; patients: m  =  228072, 
sd = 74639) and the observer rated SRRS-score (t(38) = -15.235, p < .001; 
controls: m  =  .41, sd  =  .62; patients: m  =  26.30, sd  =  6.96) differed be-
tween patients and controls. However, self-reported physical activity did 
not differ between both groups (t(38) = 1.452, p = .155; controls: m = 4502, 
sd = 6103; patients: m = 2241, sd = 3727).
There is a trend for a negative correlation between the SRRS-score and 
the objective activity level, measured by actigraphy, in patients (r = -.378, 
p = .100). This suggests that patients with the highest SRRS scores indeed 
presented also the lowest level of global activity. There is also a positive 
correlation between the objective activity level and the self-reported activity 
in patients yet lacking statistical significance (r = .337, p = .147). However, 
there is no correlation between SRRS and IPAQ (r  =  .204, p  =  .349) in 
patients.
Discussion: In this study, we demonstrated that the expert ratings (SRRS) 
correspond well to the gold standard actigrahpy, even though this associ-
ation is not significant yet. Thus, expert raters seem to rate PS correctly 
in patients. However, the self-report (IPAQ) neither corresponds well with 
the expert ratings nor the actigraphy. Thus, in evaluating PS in psychosis, 
researchers should not rely on self-report exclusively. Finally, this finding 
also suggests that patients may not perceive their physical inactivity cor-
rectly in case this was due to psychomotor slowing.
S39. THE IMPACT OF THE GROUP FACTOR 
ON OUTCOME IN GROUP THERAPY: 
FINAL RESULTS OF RCT INCLUDING 127 
SCHIZOPHRENIA OUTPATIENTS
Daniel Mueller*1, Conny Steichen1, Kristin Schaller1,  
Volker Roder1
1University Hospital of Psychiatry and Psychotherapy Bern
Background: Today, some evidence-based group therapy approaches fo-
cusing different treatment goals are available for the treatment of schiz-
ophrenia patients, e.g. psychoeducation, social skills training, CBTp or 
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cognitive remediation. However, only few if  any data are available regarding 
the impact of the group factor as an unspecific mechanism of change re-
garding outcome in schizophrenia patients. Does the participation in goal-
oriented groups per se affect therapy outcome?
Methods: To bridge this gap, a cognitive remediation group approach 
(Integrated Neurocognitive Therapy, INT) developed in our lab has 
been compared with control patients not participating in therapy groups 
(Treatment as Usual, TAU). A  total of 127 schizophrenia outpatients 
has been randomly assigned to INT (N=65) or TAU (n=62). INT was 
conducted twice a week over 15 weeks therapy duration. A comprehensive 
test battery was assessed before and after therapy as well as at 1-year follow 
up in both comparison groups. The group factor was assessed by the newly 
developed questionnaire “Experience and Behavior in Therapy groups 
EBIT”, a brief  questionnaire including 13 items.
Results: The therapy group showed significantly better effects in EBIT out-
come compared to controls regarding the global score (mean of all EBIT 
items) (GLM: F=4.23, p=.02) as well as regarding empirical 2-factor so-
lution using factor analysis: factor 1 (affect and communication skills) 
(GLM: F=3.70; p=.03) and factor 2 (eye contact during communication) 
(F=3.35, p=.04). Additionally, EBIT scores are significantly associated 
with improvement in cognition and negative symptoms after treatment but 
not with positive symptoms.
Discussion: First of all, the group factor can be identified and measured 
using a brief  questionnaire. Additionally, the group factor has a supple-
ment positive effect on cognition and negative symptoms.
S40. COMBINING PHARMACOTHERAPY 
OF BI 425809 WITH COMPUTERISED 
COGNITIVE TRAINING IN PATIENTS WITH 
SCHIZOPHRENIA: INITIAL EXPERIENCE OF 
A LARGE-SCALE MULTICENTRE RANDOMISED 
CLINICAL TRIAL
Sanjay Hake*1, Songqiao Huang2, Sean McDonald3,  
Stephane Pollentier4, Jana Podhorna4
1Boehringer Ingelheim RCV GmbH & Co KG; 2Boehringer 
Ingelheim Pharmaceuticals Inc; 3Boehringer Ingelheim (Canada) 
Ltd.; 4Boehringer Ingelheim International GmbH
Background: There are currently no approved medications for cognition in 
patients with schizophrenia. BI 425809, a glycine transporter 1 inhibitor, 
increases glycine in the synaptic cleft and may improve glutamatergic neuro-
transmission, synaptic neuroplasticity, and cognition. Pharmacotherapies 
targeting neuroplasticity may require concurrent cognitive stimulation, 
and often the surroundings of patients with schizophrenia provide only a 
low level of cognitive demand. At-home computerised cognitive training 
(CCT) should increase the level of cognitive stimulation for these patients. 
Combining CCT with pharmacotherapy could therefore improve cognition 
in patients with schizophrenia. CCT studies are currently limited in scale 
and are associated with challenges, such as patient compliance.
This ongoing study explores whether at-home CCT combined with BI 
425809 could improve cognition, as compared with patients on at-home 
CCT and placebo, in patients with schizophrenia. Here, we provide an in-
itial reflection on the experiences and challenges associated with setting 
up this large-scale clinical trial, in addition to an update on recruitment 
trajectories.
Methods: This is a Phase II, double-blind, placebo-controlled, parallel 
group trial in patients with schizophrenia on stable antipsychotic therapy, 
across ~50 centres in 6 countries. Recruitment commenced in June 2019. 
Patients (aged 18–50  years) must demonstrate compliance with CCT 
during a 2-week run-in period; this means completing at least 2 hours/
week (i.e. 4 hours total during screening). Only CCT-compliant patients 
are randomised (1:1) to BI 425809 or placebo once daily on top of CCT 
for 12 weeks. The target duration for at-home CCT is ~30 hours, across 
3–5 sessions (2.5 hours total) per week. The primary endpoint is change 
from baseline in neurocognitive composite score of the Measurement and 
Treatment Research to Improve Cognition in Schizophrenia Consensus 
Cognitive Battery after 12 weeks of treatment. Novel exploratory endpoints 
include the Virtual Reality Functional Capacity Assessment Tool to assess 
daily functioning and the Balloon Effort Task to assess motivation in cog-
nitive performance and, its association with patients’ willingness to comply 
with at-home CCT.
Results: To date, 32 patients have been screened and 11 randomised (21 
patients failed screening, primarily due to non-compliance with CCT 
run-in). The last patient out is planned for December 2020 and results are 
expected in Q1 2021. Patients randomised so far (n=11; 82% male) have a 
mean age of 33 years; those who failed screening (n=21; 67% male) have a 
mean age of 36 years. Mean MCCB total scores for the two groups are 30.9 
and 22.3; Positive and Negative Syndrome Scale (PANNS) total scores: 
71.3 vs 77.9; and PANNS negative symptom scores: 20.5 vs 20.3, for the 
randomised and screen failure patients, respectively.
Discussion: It is expected that the results of this trial will help to: indicate 
if  there is an enhanced benefit of combining pharmacotherapy with cogni-
tive stimulation through at-home CCT; and determine the role of motiva-
tion in CCT compliance and performance in patients with schizophrenia. 
The main reason for screen failures was non-compliance with CCT run-in, 
underscoring the relevance of coaching and motivational accompaniment 
to promote adherence to CCT. The results will indicate if  large-scale imple-
mentation of at-home CCT across multiple centres and several countries 
is feasible.
S41. RANDOMISED CONTROLLED TRIAL OF 
METACOGNITIVE TRAINING COMPARED 
WITH PSYCHOEDUCATION IN PATIENTS WITH 
SCHIZOPHRENIA SPECTRUM DISORDERS: 
EFFECTS ON INSIGHT
Javier-David Lopez-Morinigo*1,  
Adela Sánchez Escribano-Martínez2,  
Verónica González Ruiz-Ruano1, Laura Mata-Iturralde2,  
Sergio Sánchez-Alonso2, Laura Muñoz-Lorenzo2,  
Enrique Baca-García2, Anthony David3
1Universidad Autónoma de Madrid; 2 Universitario Fundación 
Jiménez Díaz. Madrid; 3UCL Institute of Mental Health
Background: Insight in schizophrenia spectrum disorders (SSD) has 
been linked with positive outcomes. However, the effect size of previous 
treatments on insight has been relatively small to date. The metacognitive 
basis of insight in SSD has led to speculation that metacognitive training 
(MCT) may improve insight and clinical outcomes in SSD.
Methods: Design: Single-center, assessor-blind, parallel-group, randomised 
controlled trial (RCT).
Sample: Participants are recruited from the outpatient clinic of Hospital 
Universitario Fundación Jiménez Díaz (Madrid, Spain) over June-
December 2019. Inclusion criteria: i) age: 18–64  years, both inclusive, at 
the study inception; ii) diagnosis: SSD based on the Mini International 
Neuropsychiatric Interview (Sheehan et al., 1998) and iii) IQ>70 according 
to the Wechsler Adults Intelligence Scale-IV (Wechsler, 1981). Those with 
organic and drugs-induced psychosis, poor level of Spanish and/or lack of 
cooperativeness are excluded.
Intervention: Participants are randomised to receive eight weekly group ses-
sions of MCT or group psychoeducation (PSE) and they will be assessed at: 
T0) at baseline; T1) after treatment and T2) at 1-year follow-up, although 
follow-up data are not available yet.
Co-primary outcome measures: clinical and cognitive insight dimensions, 
which will be measured by the Schedule for Assessment of Insight 
(Expanded version) (SAI-E) (Kemp & David, 1997), and the Beck Cognitive 
Insight Scale (BCIS) (Beck et al., 2004), respectively.
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